Biotech | August 02, 2021
Bharat Biotech gets WHO prequalification for ROTAVAC 5D
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The first batch will be shipped to the Gamaleya Center for the quality control
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age
Subscribe To Our Newsletter & Stay Updated
